- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Brd4 for cancer therapy: inhibitors and degraders
Authors
Keywords
-
Journal
MedChemComm
Volume -, Issue -, Pages -
Publisher
Royal Society of Chemistry (RSC)
Online
2018-08-07
DOI
10.1039/c8md00198g
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors
- (2018) Fa Zhang et al. CURRENT DRUG TARGETS
- Structure-Based Discovery and Optimization of Benzo[d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC)
- (2018) Maofeng Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer
- (2018) Qiuping Xiang et al. ACS Medicinal Chemistry Letters
- BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
- (2018) Hatice Gulcin Ozer et al. Cancer Discovery
- Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1
- (2017) Andrew P. Crew et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Bromodomain-Containing Protein 4
- (2017) Zhiqing Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor
- (2017) Keith F. McDaniel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
- (2017) Liang Ouyang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors
- (2017) Le Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen
- (2017) Alex M. Ayoub et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- BET Inhibitors as Anticancer Agents: A Patent Review
- (2017) Imran Ali et al. Recent Patents on Anti-Cancer Drug Discovery
- Drugging Undruggable Molecular Cancer Targets
- (2016) John S. Lazo et al. Annual Review of Pharmacology and Toxicology
- Bromodomains: Structure, function and pharmacology of inhibition
- (2016) Elena Ferri et al. BIOCHEMICAL PHARMACOLOGY
- A phenotypic drug discovery study on thienodiazepine derivatives as inhibitors of T cell proliferation induced by CD28 co-stimulation leads to the discovery of a first bromodomain inhibitor
- (2016) Junichi Endo et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological evaluation of dihydroquinoxalinone derivatives as BRD4 inhibitors
- (2016) Yifei Yang et al. BIOORGANIC CHEMISTRY
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins
- (2016) Brigitt Raux et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation
- (2016) Xiaoqian Xue et al. JOURNAL OF MEDICINAL CHEMISTRY
- 4-Acyl Pyrrole Derivatives Yield Novel Vectors for Designing Inhibitors of the Acetyl-Lysine Recognition Site of BRD4(1)
- (2016) Martin Hügle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153)
- (2016) Robert H. Bradbury et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
- (2016) Brian K. Albrecht et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075
- (2016) Emily J. Faivre et al. MOLECULAR CANCER RESEARCH
- AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
- (2016) G. W. Rhyasen et al. MOLECULAR CANCER THERAPEUTICS
- Roche bets on bromodomains
- (2016) Eva von Schaper NATURE BIOTECHNOLOGY
- Potent and selective bivalent inhibitors of BET bromodomains
- (2016) Michael J Waring et al. Nature Chemical Biology
- Design and characterization of bivalent BET inhibitors
- (2016) Minoru Tanaka et al. Nature Chemical Biology
- Drug developers delve into the cell's trash-disposal machinery
- (2016) Kelly Rae Chi NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitors of BRD4 as Potential Cancer Therapy
- (2016) Ahmed F. Abdel-Magid ACS Medicinal Chemistry Letters
- Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
- (2016) A. Stathis et al. Cancer Discovery
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
- (2016) Sandy Amorim et al. Lancet Haematology
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of methyl isoxazoleazepines as inhibitors of BET
- (2015) Michael C. Hewitt et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Abstract 3523: Discovery of a novel BET inhibitor INCB054329
- (2015) Phillip CC Liu et al. CANCER RESEARCH
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
- (2015) M. Boi et al. CLINICAL CANCER RESEARCH
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
- (2015) Xu Ran et al. JOURNAL OF MEDICINAL CHEMISTRY
- BET inhibitor resistance emerges from leukaemia stem cells
- (2015) Chun Yew Fong et al. NATURE
- Prime time for PROTACs
- (2015) Raymond J Deshaies Nature Chemical Biology
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Selectively targeting proteins for degradation
- (2015) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- An iridium(iii)-based irreversible protein–protein interaction inhibitor of BRD4 as a potent anticancer agent
- (2015) Hai-Jing Zhong et al. Chemical Science
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- BRD4: A BET(ter) target for the treatment of AML?
- (2014) Peter Valent et al. CELL CYCLE
- An epigenomic approach to therapy for tamoxifen-resistant breast cancer
- (2014) Qin Feng et al. CELL RESEARCH
- BET bromodomain proteins are required for glioblastoma cell proliferation
- (2014) Chiara Pastori et al. Epigenetics
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor
- (2014) Romain Gosmini et al. JOURNAL OF MEDICINAL CHEMISTRY
- Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors
- (2014) Michael R McKeown et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- The new frontier of genome engineering with CRISPR-Cas9
- (2014) J. A. Doudna et al. SCIENCE
- 4-Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
- (2013) Xavier Lucas et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer
- (2013) Robert H. Bradbury et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762
- (2013) A. Chaidos et al. BLOOD
- BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
- (2013) M. F. Segura et al. CANCER RESEARCH
- Naphthyridines as Novel BET Family Bromodomain Inhibitors
- (2013) Olivier Mirguet et al. ChemMedChem
- Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
- (2013) T. Shimamura et al. CLINICAL CANCER RESEARCH
- Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
- (2013) Olivier Mirguet et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Drug Discovery of 2-Thiazolidinones as Inhibitors of the Histone Reader BRD4 Bromodomain
- (2013) Lele Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
- (2013) Yujun Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands
- (2013) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- Histone Deacetylases as Targets for Multiple Diseases
- (2013) Jaiprakash N Sangshetti et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
- (2013) S. A. Loddick et al. MOLECULAR CANCER THERAPEUTICS
- BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models
- (2013) Anastasia Wyce et al. PLoS One
- Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
- (2013) Victor S. Gehling et al. ACS Medicinal Chemistry Letters
- From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151
- (2012) Olivier Mirguet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)
- (2012) Jonathan Seal et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit
- (2012) Paul V. Fish et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains
- (2012) Duncan Hay et al. MedChemComm
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- 3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands
- (2011) David S. Hewings et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
- (2011) Chun-wa Chung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery
- (2011) Chun-wa Chung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides
- (2011) Paul Bamborough et al. JOURNAL OF MEDICINAL CHEMISTRY
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic Resolution
- (2009) Friederike Vollmuth et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bromodomain 4 activation predicts breast cancer survival
- (2008) N. P. S. Crawford et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now